-
Mashup Score: 13At SUO, Failure Takes Center Stage - 6 year(s) ago
As a medical student, I had never considered urology as a specialty. But after a brief rotation, I was immediately drawn to the field’s constant …
Source: opmed.doximity.comCategories: UrologyTweet
-
Mashup Score: 1
SUO 2019 immunotherapy and bladder cancer, metastatic model, depletion of Treg cells in bladder cancer, anti-PD-L1 therapy, intravesical MB49 model of bladder cancer, neoadjuvant treatment.
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Immunotherapy in #BladderCancer: Targets and surgical timing. Presentation by Karen Wheeler, MD @UTHealthSA. Coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/qg1b11hzcL @SUO_YUO @UroOnc https://t.co/ipxwPTVsCd
-
-
Mashup Score: 0SUO 2019: Employing Multiparametric Profiling to Characterize Immunotherapy Responders in Clear Cell Renal Cell Carcinoma - 6 year(s) ago
SUO 2019 multiparametric profiling to characterize immunotherapy responders in clear cell renal cell carcinoma (ccRCC), combination therapies in RCC, immunophenotype and mutational profiles in metastatic ccRCC
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Employing multiparametric profiling to characterize immunotherapy responders in clear cell RCC. Presentation by Brandon Manley, MD @MoffittNews. Written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/7ubVY44JRH @SUO_YUO @UroOnc
-
-
Mashup Score: 0SUO 2019: PARP Inhibitors for Prostate Cancer - 6 year(s) ago
SUO 2019 PARP inhibitors in prostate cancer Joaquin Mateo, potential additional targets for tailored treatment TOPARP trial, DNA-repair defects responded to the PARP inhibitor olaparib, Implementing PARP inhibitors in clinical practice.
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 PARP inhibitors for #ProstateCancer. Presented by @quimmateo @VHIO. Written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/kZ9rAeVWyv @SUO_YUO @UroOnc
-
-
Mashup Score: 3SUO 2019: Bipolar Androgen Therapy for Men with Castration Resistant Prostate Cancer - 6 year(s) ago
SUO 2019 bipolar androgen therapy (BAT) for men with castration-resistant prostate cancer, Samuel Denmeade, three phases of androgen inhibition: shock, adaptation, and resistance, TRANSFORMER phase II trial.
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Bipolar androgen therapy for men with castration-resistant #ProstateCancer. Presentation by @denmesa @HopkinsMedicine. Coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/zjR8QmPX4p @SUO_YUO @UroOnc https://t.co/qtYVPUE5cg
-
-
Mashup Score: 8
SUO 2019 the current landscape of metastatic castration sensitive prostate cancer (mCSPC), Sweeney, treatment benefit for overall survival in mCSPC, GETUG15, CHAARTED, STAMPEDE, ENZAMET
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Optimal management of mCSPC. Presentation by @ChrisSweens1 @DanaFarber. Coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/csyBMl8JDL @SUO_YUO @UroOnc #ProstateCancer https://t.co/9XXAuWJgKS
-
-
Mashup Score: 4
SUO 2019 State of the Art Lecture at the Society of Urologic Oncology Annual Meeting, the landscape of advanced bladder cancer following the working of The Cancer Genome Atlas (TCGA) project, the genomic and molecular underpinnings of urothelial carcinoma, the germline, rather than somatic, genomic landscape of advanced bladder cancer.
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 State of the Art II: The post TCGA landscape of #BladderCancer. Presented by Seth Lerner, MD, FACS @bcmhouston. Written coverage by @WallisCJD @VUMChealth > https://t.co/5cDYEeYTuW @SUO_YUO @UroOnc https://t.co/YiZkTabUQf
-
-
Mashup Score: 2SUO 2019: Radiotherapy after Radical Prostatectomy: Effect of Timing of Post-Prostatectomy Radiation on Functional Outcomes - 6 year(s) ago
SUO 2019 effect of the timing of post-prostatectomy radiotherapy on functional outcomes, patient-reported sexual, urinary and bowel related outcomes following post-operative radiotherapy, CEASAR study
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Radiotherapy after radical prostatectomy: effect of timing of post-prostatectomy radiation on functional outcomes. Presented by Heather Huelster, MD @VUMChealth. Written coverage by @WallisCJD on UroToday > https://t.co/FyF09VwTi6 @SUO_YUO @UroOnc https://t.co/fBsfANoMMo
-
-
Mashup Score: 6
SUO 2019 transperineal vs transrectal ultrasound-guided systematic (TRUS) prostate biopsy, cost efficacy of performing transperineal and TRUS in the office, six prostate biopsy strategies in-office
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Transperineal vs transrectal ultrasound-guided systematic biopsy: understanding the true costs utilizing time-driven activity-based costing. Presented by Aaron Lavianam, MD @VUMChealth. Coverage by @WallisCJD on UroToday > https://t.co/U0vwETTwRD @SUO_YUO @UroOnc https://t.co/3RHCodoLeX
-
-
Mashup Score: 0SUO 2019: Heterogeneity in Policy Effect: Changes in Prostate Cancer Screening Associated with ACO Participation - 6 year(s) ago
SUO 2019 Prostate cancer screening using serum prostate-specific antigen (PSA) testing, changes in PSA screening with participation in Accountable Care Organizations, impact of changes in reimbursement on PSA screening
Source: www.urotoday.comCategories: Rare DiseaseTweet-
#SUO19 Heterogeneity in policy effect: changes in #ProstateCancer screening associated with ACO participation. Presentation by @AmyLuckenbaugh @VUMChealth. Written coverage by @WallisCJD on UroToday > https://t.co/15OAsMHYzg @SUO_YUO @UroOnc https://t.co/6sqxtXFzuW
-
RT @UNCurology: At #SUO19, Failure Takes Center Stage https://t.co/IhMAUY9NMG @doximity Op-Med from @angiesmith_uro on spectacular and pro…